Introduction to Intrauterine Adhesions

Intrauterine adhesions (IUAs), often referred to as Asherman’s syndrome, represent a significant clinical challenge in reproductive medicine. These fibrotic bands form within the uterine cavity typically following trauma, such as curettage, or infections. Consequently, patients often face symptoms ranging from menstrual irregularities to secondary infertility. While surgical adhesiolysis remains the standard treatment, the high rate of recurrence necessitates more effective Intrauterine Adhesions Prevention strategies.

The β-GP-CS/SA Hydrogel Technology

Recent research published in the Journal of Biomaterials Science has introduced a promising solution: a thermo-sensitive hydrogel composed of β-Glycerophosphate-Chitosan and Sodium Alginate (β-GP-CS/SA). This material incorporates aspirin (ASA) as a primary anti-inflammatory agent. One of the most significant features of this hydrogel is its thermo-responsive nature. Specifically, the material remains a liquid (sol) at room temperature but undergoes gelation within five minutes when exposed to physiological temperatures (37°C).

Moreover, the resulting elastic gel provides a stable physical barrier with an interconnected porous microarchitecture. This structure is crucial because it facilitates controlled drug delivery and allows for cellular migration. Data indicates that the hydrogel loses approximately 87% of its mass over 14 days, matching the typical timeline for endometrial healing. During this period, it releases about 60% of its aspirin content in a sustained manner, ensuring a prolonged therapeutic effect.

Mechanisms of Intrauterine Adhesions Prevention

Aspirin plays a dual role in this system. Beyond its well-known anti-inflammatory properties, aspirin specifically targets the molecular pathways of fibrosis. Studies demonstrate that the gel significantly suppresses fibrogenic markers, including Collagen I and α-SMA. Furthermore, the material enhances the expression of Vascular Endothelial Growth Factor (VEGF), which is essential for healthy endometrial angiogenesis and tissue regeneration.

In vivo experiments have shown that the implantation of this ASA-loaded gel markedly attenuates adhesion formation. It preserves endometrial morphology and reduces stromal fibrosis without causing any adverse hepatic or renal lesions. By combining physical isolation with bioactive therapeutic release, this hydrogel addresses the two primary needs of Intrauterine Adhesions Prevention: preventing tissue contact and inhibiting the inflammatory-fibrotic cascade.

Clinical Implications for Gynecologists

For clinicians, this technology represents a "smart" barrier. Traditional methods like intrauterine devices (IUDs) or balloon catheters provide mechanical separation but do not actively promote tissue repair. In contrast, the β-GP-CS/SA hydrogel offers a biodegradable alternative that actively modifies the wound environment. This dual-action approach could potentially improve pregnancy rates and long-term reproductive outcomes for women undergoing uterine procedures.

Frequently Asked Questions

What are the primary causes of intrauterine adhesions?

IUAs are most commonly caused by trauma to the basal layer of the endometrium during procedures like dilation and curettage (D&C), hysteroscopic surgery, or as a result of pelvic inflammatory disease (PID).

How does aspirin assist in preventing uterine scarring?

Aspirin inhibits the TGF-β1-Smad signaling pathway, which is a major driver of fibrosis. By suppressing this pathway and promoting blood vessel growth (angiogenesis), it helps the endometrium heal without forming scar tissue.

Why is a thermo-sensitive hydrogel preferred over solid barriers?

Thermo-sensitive hydrogels can be injected easily as a liquid to fill the entire uterine cavity before gelling. This ensures a more comprehensive physical barrier than solid sheets or devices, and the gel naturally biodegrades, eliminating the need for a second procedure to remove it.

Disclaimer: This content is for informational and educational purposes only. It does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Ma H et al. Aspirin-loaded thermo-sensitive chitosan-sodium alginate hydrogel for the prevention of intrauterine adhesions. J Biomater Sci Polym Ed. 2026 Apr 29. doi: 10.1080/09205063.2026.2651261. PMID: 42052865.

Zhang Z et al. Aspirin inhibits endometrial fibrosis by suppressing the TGF-β1-Smad2/Smad3 pathway in intrauterine adhesions. Int J Mol Med. 2020 May;45(5):1351-1360. doi: 10.3892/ijmm.2020.4506.

FDA Grants Approval to intrauterine device for Preventing Uterine Adhesions. Medical Dialogues. September 19, 2025.